Breast Cancer

Data confirm combination therapy improves breast cancer survival in fit women

Published in Women's Health Weekly, December 1st, 2005

New data confirm that the Xeloda (capecitabine) and Taxotere (docetaxel) combination improves survival time by an important 3 months in younger or fitter women with an aggressive form of breast cancer that has spread to other parts of the body (metastatic).

This is the first study designed to show that taking the two potent drugs together improves women's survival when compared to the more commonly used 'sequential treatment' approach of taking Taxotere alone followed by Xeloda alone. The study noted a slight increase in the known manageable side effects of the two drugs, but this is more than compensated by the prospect of increased survival.

These...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2005-12-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry